Metformin vs Rapamycin

Head-to-head comparison of Metformin (Metformin Hydrochloride) and Rapamycin (Rapamycin (Sirolimus)) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyMetforminRapamycin
CategoryAnti-AgingAnti-Aging
Full NameMetformin HydrochlorideRapamycin (Sirolimus)
Molecular Weight165.63 Da914.17 Da
Half-Life4-8.7 hours~62 hours
Amino AcidsN/AN/A
Typical Dose500-2000 mg/day0.5-6 mg/week
RouteOralOral
Purity≥98%≥98%
Studies Count40001500
Research StatusClinicalClinical

Metformin Benefits

  • AMPK activation
  • improved insulin sensitivity
  • reduced oxidative stress
  • population-level longevity signal

Rapamycin Benefits

  • mTOR inhibition
  • autophagy activation
  • cellular senescence modulation
  • lifespan extension in model organisms

Metformin Dosing

500-2000 mg/day oral|start low and titrate in trials|taken with meals

Rapamycin Dosing

0.5-6 mg oral weekly in studies|intermittent dosing protocols|clinical monitoring for tolerability

Metformin Side Effects

  • gastrointestinal upset
  • vitamin B12 reduction
  • diarrhea
  • rare lactic acidosis

Rapamycin Side Effects

  • mouth ulcers
  • elevated lipids
  • immunosuppression
  • glucose intolerance

Research Overview

Metformin

Metformin has extensive human data and remains a leading candidate in geroscience research. Observational and mechanistic studies suggest it may influence pathways tied to aging, though definitive anti-longevity proof in healthy humans is still lacking.

Rapamycin

Rapamycin extends lifespan in multiple model organisms and is a cornerstone compound in longevity biology. Human studies focus on immune function, inflammation, and age-related biomarkers rather than proven lifespan extension.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Metformin stacks with:

RapamycinNMNSpermidine

Rapamycin stacks with:

MetforminSpermidineNMN
AMPKinsulin-sensitivitygerosciencemetabolismmTORautophagylongevity